WOCKHARDT
Quarterly Results Analysis [Sep2024]
WOCKHARDT Quarterly Results
Consolidated | Sep2024 Audited |
Jun2024 UnAudited |
Mar2024 UnAudited |
Dec2023 UnAudited |
Sep2023 UnAudited |
Jun2023 UnAudited |
Mar2023 UnAudited |
Dec2022 UnAudited |
---|---|---|---|---|---|---|---|---|
Revenues | ₹809 Cr | ₹739 Cr | ₹700 Cr | ₹701 Cr | ₹753 Cr | ₹644 Cr | ₹678 Cr | ₹699 Cr |
Expenses | ₹699 Cr | ₹648 Cr | ₹803 Cr | ₹664 Cr | ₹681 Cr | ₹628 Cr | ₹675 Cr | ₹654 Cr |
Operating Income | ₹110 Cr | ₹91 Cr | ₹-103 Cr | ₹37 Cr | ₹72 Cr | ₹16 Cr | ₹3 Cr | ₹45 Cr |
Other Income | ₹9 Cr | ₹30 Cr | ₹54 Cr | ₹8 Cr | ₹24 Cr | ₹14 Cr | ₹32 Cr | ₹2 Cr |
Interest | ₹73 Cr | ₹73 Cr | ₹73 Cr | ₹77 Cr | ₹76 Cr | ₹79 Cr | ₹76 Cr | ₹83 Cr |
Depreciation | ₹55 Cr | ₹54 Cr | ₹58 Cr | ₹55 Cr | ₹55 Cr | ₹55 Cr | ₹56 Cr | ₹66 Cr |
Profit Before Tax | ₹-9 Cr | ₹-6 Cr | ₹-180 Cr | ₹-87 Cr | ₹-35 Cr | ₹-118 Cr | ₹-193 Cr | ₹-105 Cr |
Profit After Tax | ₹-16 Cr | ₹-16 Cr | ₹-177 Cr | ₹-86 Cr | ₹-73 Cr | ₹-136 Cr | ₹-237 Cr | ₹-102 Cr |
EPS | ₹-1.43 | ₹-0.91 | ₹-10.97 | ₹-5.76 | ₹-5.35 | ₹-9.31 | ₹-14.44 | ₹-6.67 |
Industry Peers & Returns | 1W | 1M | 1Y |
WOCKHARDT | -1.2% | 10.2% | 266.4% |
SUN PHARMACEUTICAL INDUSTRIES | 1% | 4.6% | 47.5% |
CIPLA | -1.1% | -0.3% | 20.7% |
DR REDDYS LABORATORIES | 2.2% | 12.1% | 21.6% |
ZYDUS LIFESCIENCES | -2.7% | 0.8% | 43.8% |
DIVIS LABORATORIES | 1% | -3.2% | 59.3% |
MANKIND PHARMA | 0.8% | 12.8% | 52.4% |
TORRENT PHARMACEUTICALS | -1.5% | 5.9% | 55% |
LUPIN | 0.9% | 7.2% | 72.7% |
WOCKHARDT Quarterly Revenues
Revenues | |
---|---|
Q-o-Q | 9.47 % |
Y-o-Y | 7.44 % |
Quarters | Revenues | % Change | |
---|---|---|---|
Sep2024 | ₹809 Cr | 9.47 | |
Jun2024 | ₹739 Cr | 5.57 | |
Mar2024 | ₹700 Cr | -0.14 | |
Dec2023 | ₹701 Cr | -6.91 | |
Sep2023 | ₹753 Cr | 16.93 | |
Jun2023 | ₹644 Cr | -5.01 | |
Mar2023 | ₹678 Cr | -3.00 | |
Dec2022 | ₹699 Cr | - |
WOCKHARDT Quarterly Operating Profit
Operating Profit | |
---|---|
Q-o-Q | 20.88 % |
Y-o-Y | 52.78 % |
Quarters | Operating Profit | % Change | |
---|---|---|---|
Sep2024 | ₹110 Cr | 20.88 | |
Jun2024 | ₹91 Cr | Positive | |
Mar2024 | ₹-103 Cr | Negative | |
Dec2023 | ₹37 Cr | -48.61 | |
Sep2023 | ₹72 Cr | 350.00 | |
Jun2023 | ₹16 Cr | 433.33 | |
Mar2023 | ₹3 Cr | -93.33 | |
Dec2022 | ₹45 Cr | - |
Operating Margins | |
---|---|
Q-o-Q | 10.48 % |
Y-o-Y | 42.26 % |
Quarters | Operating Margin% | % Change | |
---|---|---|---|
Sep2024 | 13.6% | 10.48 | |
Jun2024 | 12.31% | Positive | |
Mar2024 | -14.71% | Negative | |
Dec2023 | 5.28% | -44.77 | |
Sep2023 | 9.56% | 285.48 | |
Jun2023 | 2.48% | 463.64 | |
Mar2023 | 0.44% | -93.17 | |
Dec2022 | 6.44% | - |
WOCKHARDT Quarterly Profit After Tax
Profit After Tax(PAT) | |
---|---|
Q-o-Q | Negative |
Y-o-Y | Negative |
Quarters | Profit After Tax | % Change | |
---|---|---|---|
Sep2024 | ₹-16 Cr | Negative | |
Jun2024 | ₹-16 Cr | Negative | |
Mar2024 | ₹-177 Cr | Negative | |
Dec2023 | ₹-86 Cr | Negative | |
Sep2023 | ₹-73 Cr | Negative | |
Jun2023 | ₹-136 Cr | Negative | |
Mar2023 | ₹-237 Cr | Negative | |
Dec2022 | ₹-102 Cr | - |
PAT Margins | |
---|---|
Q-o-Q | Negative |
Y-o-Y | Negative |
Quarters | PAT Margin(%) | % Change | |
---|---|---|---|
Sep2024 | -1.98 % | Negative | |
Jun2024 | -2.17 % | Negative | |
Mar2024 | -25.29 % | Negative | |
Dec2023 | -12.27 % | Negative | |
Sep2023 | -9.69 % | Negative | |
Jun2023 | -21.12 % | Negative | |
Mar2023 | -34.96 % | Negative | |
Dec2022 | -14.59 % | - |
WOCKHARDT Quarterly Earnings Per Share (EPS)
EPS | |
---|---|
Q-o-Q | Negative |
Y-o-Y | Negative |
Quarters | EPS | % Change | |
---|---|---|---|
Sep2024 | ₹-1.43 | Negative | |
Jun2024 | ₹-0.91 | Negative | |
Mar2024 | ₹-10.97 | Negative | |
Dec2023 | ₹-5.76 | Negative | |
Sep2023 | ₹-5.35 | Negative | |
Jun2023 | ₹-9.31 | Negative | |
Mar2023 | ₹-14.44 | Negative | |
Dec2022 | ₹-6.67 | - |
You may also like the below Video Courses
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs MANKIND PHARMA LTD